What is the 13F Pro Quality Score for LTRN?

13F Pro ranks Lantern Pharma Inc. (LTRN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LTRN's current score at https://13fpro.ai/research/LTRN (free sign-up required for the full ranking).

Where does 13F Pro source LTRN data?

All Lantern Pharma Inc. fundamentals and ownership data come directly from SEC EDGAR. Lantern Pharma Inc. files with the SEC under CIK 1763950. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LTRN in?

Lantern Pharma Inc. (LTRN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LTRN research updated on 13F Pro?

LTRN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lantern Pharma Inc.(LTRN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1763950 LTRN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

LTRN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lantern Pharma Inc. (LTRN), a Healthcare sector company. LTRN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Lantern Pharma Inc. reports net income of $-3.3M, free cash flow of $-3.8M. Top institutional holders of LTRN by reported 13-F value include BIOS Capital Management,, VANGUARD CAPITAL MANAGEMENT, CM Management,, based on the most recent SEC filings. LTRN trades on the Nasdaq exchange and files with the SEC under CIK 1763950. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LTRN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lantern Pharma Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-3.3M

Free Cash Flow

Q1 2026

$-3.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+17.6% YoY

$-17.1MFY 2025

FY22 $-14.3MFY23 $-16.0MFY24 $-20.8MFY25 $-17.1M

Operating Income

+19.1% YoY

$-18.0MFY 2025

FY22 $-14.4MFY23 $-17.9MFY24 $-22.2MFY25 $-18.0M

EPS (Diluted)

+18.7% YoY

$-1.57FY 2025

FY22 $-1.31FY23 $-1.47FY24 $-1.93FY25 $-1.57

Total Assets

-56.8% YoY

$11.0MFY 2025

FY22 $58.8MFY23 $43.6MFY24 $25.6MFY25 $11.0M

Op. Cash Flow

+12.0% YoY

$-15.7MFY 2025

FY22 $-12.8MFY23 $-14.3MFY24 $-17.8MFY25 $-15.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2018
Net Income	$-17.1M +17.6%	$-20.8M -30.2%	$-16.0M -11.9%	$-14.3M -15.3%	$-12.4M	—
Operating Income	$-18.0M +19.1%	$-22.2M -24.3%	$-17.9M -23.9%	$-14.4M -14.6%	$-12.6M	—
EPS (Diluted)	$-1.57 +18.7%	$-1.93 -31.3%	$-1.47 -12.2%	$-1.31	—	—
Total Assets	$11.0M -56.8%	$25.6M -41.4%	$43.6M -25.8%	$58.8M -20.4%	$74.0M	—
Operating Cash Flow	$-15.7M +12.0%	$-17.8M -24.2%	$-14.3M -12.4%	$-12.8M -20.5%	$-10.6M	—

AI Insight: LTRN Financial Trends

Lantern is burning through equity at an accelerating pace with no revenue generation; equity has eroded 90% from Q2 2024 to Q1 2026.

• Equity collapsed from $31M (Q2 2024) to $3M (Q1 2026), a 90% decline over 8 quarters with no stabilization visible.

• Net losses narrowed from $5–6M per quarter (2024) to $3–4M (2025–Q1 2026), suggesting some cost discipline despite zero revenue.

• Operating cash flow consistently negative; no improvement trajectory. Q1 2026 burn was $4M on minimal operating scale.

⚠ Equity now at $3M—critical solvency threshold. Any further losses risk balance sheet insolvency within 1–2 quarters.

⚠ Zero revenue across entire 8-quarter window indicates pipeline failure or extreme pre-commercialization stage; clinical/regulatory catalyst unknown.

AI Insight: LTRN Ratio Trends

Lantern Pharma remains unprofitable with deteriorating returns; ROE collapsed to -174.3% in Q3 2025 before data gaps emerge.

• ROE declined sharply from -64.1% in Q2 2024 to -174.3% in Q3 2025, indicating worsening losses relative to shareholder equity.

• ROA also deteriorated, falling from -55.8% in Q2 2024 to -99.5% in Q2 2025, reflecting mounting asset-base losses.

⚠ Data gaps for Q4 2025 and Q1 2026 obscure latest profitability trajectory; Q3 2025 marked worst ROE on record in available history.

⚠ Margin and leverage metrics unavailable throughout; cash burn sustainability and capital structure health cannot be assessed.

Get alerted when LTRN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lantern Pharma Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LTRN

BIOS Capital Management, LP
$1.2M864,435 sh
VANGUARD CAPITAL MANAGEMENT LLC
$454.9K332,079 sh
CM Management, LLC
$342.5K250,000 sh
RENAISSANCE TECHNOLOGIES LLC
$158.9K116,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$153.0K111,646 sh
Westside Investment Management, Inc.
$68.6K50,050 sh
Voss Capital, LP
$68.5K50,000 sh
VANGUARD FIDUCIARY TRUST CO
$68.0K49,607 sh
BlackRock, Inc.
$62.0K45,267 sh
DIMENSIONAL FUND ADVISORS LP
$52.1K38,060 sh

Fund	Value	Shares
BIOS Capital Management, LP	$1.2M	864,435
VANGUARD CAPITAL MANAGEMENT LLC	$454.9K	332,079
CM Management, LLC	$342.5K	250,000
RENAISSANCE TECHNOLOGIES LLC	$158.9K	116,000
GEODE CAPITAL MANAGEMENT, LLC	$153.0K	111,646
Westside Investment Management, Inc.	$68.6K	50,050
Voss Capital, LP	$68.5K	50,000
VANGUARD FIDUCIARY TRUST CO	$68.0K	49,607
BlackRock, Inc.	$62.0K	45,267
DIMENSIONAL FUND ADVISORS LP	$52.1K	38,060

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LTRN on your watchlist

Track score changes the day Lantern Pharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LTRN a good stock to buy?

13F Pro's AI-powered analysis of Lantern Pharma Inc. (LTRN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LTRN are available on the LTRN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LTRN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LTRN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lantern Pharma Inc.'s investment landscape.